Randy Longman is a Gastroenterology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1315 York Ave
Mezzanine
New York, NY 100215304
Telephone
212-746-5077Registry record last updated 19 Sept 2013.
Clinical trials
- Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Sponsor: Weill Medical College of Cornell University
- Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis
Sponsor: Weill Medical College of Cornell University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- ABBVIE INC.Program year20251 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
70.7%Interleukin-12 Antagonist39.7%Stelara100%Part D<11 patientsJAK inhibitor31%Rinvoq100%Part D<11 patientsMetabolism & gastrointestinal
29.3%Aminosalicylate29.3%Mesalamine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
9 NIH research awards on record, funded 2013–2026 per NIH RePORTER. The latest:
- Activity Probes to Guide Precision Microbiome Therapy
Weill Medical Coll of Cornell Univ
FY2026$3,274,705R01AT013241 - Agr2 regulates host-microbe responses in Crohn's disease
Weill Medical Coll of Cornell Univ
FY2026$847,414R01DK140463 - TL1A Regulation of Group 3 Innate Lymphoid Cells in Colitis
Weill Medical Coll of Cornell Univ
FY2026$668,149R01DK120985
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”